Internal Medicine, Hematology & Oncology · Morgantown, WV
NPI
1801999750
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
6
Medicare group memberships
Hospitals
5
Hospital affiliations
1 Medical Center Drive
Morgantown, WV, 26506
Phone (304) 598-4000
Groups this clinician bills Medicare through
Medicare paid, 2024
$53K
856 services
Medicare patients, 2024
347
Average age 74
Drug cost, 2024
$4.6M
1,078 prescriptions
Company payments, 2025
$3,646
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael D Craig was code 99214 (office e&m - established), 204 times for 141 patients. In total Michael D Craig billed 856 services in 13 codes, and Medicare paid $53K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-07-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 204 | 141 | $68.42 | $14K |
| 99213 Office E&M - Established | Facility | 175 | 147 | $43.24 | $7,567 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 174 | 101 | $13.21 | $2,299 |
| 99215 Office E&M - Established | Facility | 155 | 90 | $102.59 | $16K |
| 99205 Office E&M - New | Facility | 44 | 44 | $119.87 | $5,274 |
| 99204 Office E&M - New | Facility | 29 | 29 | $85.88 | $2,490 |
| 99214 Office E&M - Established | Office | 23 | 21 | $97.08 | $2,233 |
By year: 2022 $57K for 717 services; 2023 $65K for 829 services; 2024 $53K for 856 services.
Medicare prescription drug claims, 2024
In 2024, the drug Michael D Craig prescribed most often to Medicare patients was Anastrozole, with 86 prescriptions and refills. In total Michael D Craig wrote 1,078 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 86 | 183 | 28 | $3,079 |
| Prednisone Generic | 55 | 61 | 14 | $302 |
| Ondansetron Hcl Generic | 54 | 54 | 30 | $393 |
| Letrozole Generic | 52 | 125 | 18 | $1,423 |
| Hydroxyurea Generic | 51 | 107 | 15 | $2,019 |
| Acyclovir Generic | 48 | 104 | 14 | $1,793 |
| Abiraterone Acetate Generic | 44 | 44 | Under 11 | $71K |
| Revlimid Lenalidomide | 41 | 41 | Under 11 | $751K |
| Xtandi Enzalutamide | 38 | 38 | Under 11 | $543K |
| Ibrance Palbociclib | 38 | 38 | Under 11 | $670K |
| Potassium Chloride Generic | 32 | 80 | 12 | $1,735 |
| Prochlorperazine Maleate Generic | 29 | 30 | 15 | $357 |
| Tagrisso Osimertinib Mesylate | 28 | 28 | Under 11 | $484K |
| Erleada Apalutamide | 27 | 27 | Under 11 | $388K |
| Tamoxifen Citrate Generic | 22 | 56 | Under 11 | $705 |
Brand drugs: 316 claims; generic drugs: 762 claims; opioid claims: 51.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael D Craig $3,646 ($3,646 in general payments such as food, travel and fees) from 20 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $2,164.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 7 | $2,164 |
| Janssen Biotech, Inc. JNJ | 4 | $296 |
| Novartis Pharmaceuticals Corporation NVS | 14 | $200 |
| E.R. Squibb & Sons, L.L.C. BMY | 4 | $155 |
| Geron Corporation GERN | 1 | $135 |
| Pfizer Inc. PFE | 6 | $130 |
| Abbvie Inc. ABBV | 3 | $65.99 |
| Merck Sharp & Dohme LLC MRK | 2 | $60.4 |
| Tempus AI, Inc TEM | 3 | $60.31 |
| Genentech USA, Inc. ROG.SW | 3 | $59.17 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.